Invizius

Chapelhall, United Kingdom

Founded in 2022

  • Targeting complement system for dialysis.

  • What is the issue to solve?

    Addressing excessive complement activation in patients undergoing extracorporeal therapies.

  • What’s their solution?

    Addressing excessive complement activation in patients undergoing extracorporeal therapies using a proprietary down-regulator technology.

  • Who is their product for?

    Patients undergoing extracorporeal therapies susceptible to complement activation.

Competitors

AI Disclaimer

We have generated these company profiles using AI and feeding it the companies website. Because of that we cannot guarantee the accuracy and we welcome any feedback, we will promptly change any inaccuracies.

Thank you!